Investigational drug · Phase 2
LAM-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sarcoidosis Associated Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases and Hypoxia.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "LAM-001"
First trial start
2023
Aug 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LAM-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcoidosis Associated Pulmonary Hypertension
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "LAM-001" as an intervention, largest first.
IRulya Therapeutics Inc.Industry
NCT05798923 · 85 participants (planned) · Start Aug 30, 2023 · Primary completion Mar 2028
Drug: Placebo; LAM-001 · For: Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Sites: Tucson, Arizona; New Haven, Connecticut; Boston, Massachusetts · 4 sites in all
IRulya Therapeutics Inc.Industry
NCT07886554 · 60 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: Placebo; LAM-001 and 1 more · For: Sarcoidosis Associated Pulmonary Hypertension
Sites: Philadelphia, Pennsylvania
Steven Hays, MDAcademic, hospital or other
NCT06018766 · 30 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 2026
Drug: LAM-001; Placebo · For: Bronchiolitis Obliterans Syndrome; Chronic Lung Allograft Dysfunction; Lung Transplantation
Sites: San Francisco, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.